Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Heymans

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Journal of Medicinal Chemistry|April 16, 1993
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazinesA Lamouri, F Heymans, F Tavet, et al.
Journal of Lipid Mediators|February 1, 1992
Production and characterization of antibodies to platelet-activating factorJ L Macpherson, B Spur, S G Pyne, et al.
European Journal of Pharmacology|November 19, 1986
Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigsE Coëffier, M C Borrel, J Lefort, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic seriesF Heymans, G Dive, A Lamouri, et al.
Biochimica Et Biophysica Acta|November 23, 1981
New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixturesF Heymans, E Michel, M C Borrel, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Preventive effects of two PAF-antagonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injuryF Massicot, A Lamouri, C Martin, et al.
Journal of Medicinal Chemistry|May 1, 1987
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activityJ J Godfroid, C Broquet, S Jouquey, et al.
Lipids|December 1, 1991
PAF receptor and "Cache-oreilles" effect. Simple PAF antagonistsJ Lamotte-Brasseur, F Heymans, G Dive, et al.
Pathologie-Biologie|August 19, 2000
[Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601]M Martin, N Serradji, N Dereuddre-Bosquet, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophagesM Martin, N Serradji, N Dereuddre-Bosquet, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Journal of Medicinal Chemistry|April 16, 1993
Design and modeling of new platelet-activating factor antagonists. 1. Synthesis and biological activity of 1,4-bis(3',4',5'-trimethoxybenzoyl)-2-[[(substituted carbonyl and carbamoyl)oxy]methyl]piperazinesA Lamouri, F Heymans, F Tavet, et al.
Journal of Lipid Mediators|February 1, 1992
Production and characterization of antibodies to platelet-activating factorJ L Macpherson, B Spur, S G Pyne, et al.
European Journal of Pharmacology|November 19, 1986
Effects of PAF-acether and structural analogues on platelet activation and bronchoconstriction in guinea-pigsE Coëffier, M C Borrel, J Lefort, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Design and modeling of new platelet-activating factor antagonists. 3. Relative importance of hydrophobicity and electronic distribution in piperazinic seriesF Heymans, G Dive, A Lamouri, et al.
Biochimica Et Biophysica Acta|November 23, 1981
New total synthesis and high resolution 1H NMR spectrum of platelet-activating factor, its enantiomer and racemic mixturesF Heymans, E Michel, M C Borrel, et al.
Journal of Lipid Mediators and Cell Signalling|January 1, 1997
Preventive effects of two PAF-antagonists, PMS 536 and PMS 549, on cyclosporin-induced LLC-PK1 oxidative injuryF Massicot, A Lamouri, C Martin, et al.
Journal of Medicinal Chemistry|May 1, 1987
Structure-activity relationship in PAF-acether. 3. Hydrophobic contribution to agonistic activityJ J Godfroid, C Broquet, S Jouquey, et al.
Lipids|December 1, 1991
PAF receptor and "Cache-oreilles" effect. Simple PAF antagonistsJ Lamotte-Brasseur, F Heymans, G Dive, et al.
Pathologie-Biologie|August 19, 2000
[Antiretroviral ant anti-inflammatory properties of a novel platelet activation factor antagonist, PMS-601]M Martin, N Serradji, N Dereuddre-Bosquet, et al.
Antimicrobial Agents and Chemotherapy|October 19, 2000
PMS-601, a new platelet-activating factor receptor antagonist that inhibits human immunodeficiency virus replication and potentiates zidovudine activity in macrophagesM Martin, N Serradji, N Dereuddre-Bosquet, et al.
Pageof 4